Table 2.

Prevalence of peripheral neuropathy and symptomatic peripheral neuropathy over time.

	CD4>350 cells/µl			VL≤400 copies/ml			All patients
Week since ART initiation	N	Neuropathy [% (95% CI)]	Symptomatic neuropathy [% (95% CI)]	N	Neuropathy [% (95% CI)]	Symptomatic neuropathy [% (95% CI)]	N	Neuropathy [% (95% CI)]	Symptomatic neuropathy [% (95% CI)]
0	143	25.9 (18.9–33.9)	2.8 (0.8–7.0)	0	–	–	514	22.6 (19.0–26.4)	4.3 (2.7–6.4)
48	785	25.1 (22.1–28.3)	8.0 (6.2–10.2)	1276	29.1 (26.5–31.6)	10.0 (8.4–11.7)	1419	29.7 (27.3–32.1)	10.1 (8.6–11.8)
96	1069	29.2 (26.5–32.0)	7.7 (6.1–9.4)	1420	31.4 (29.1–33.9)	8.5 (7.1–10.1)	1598	31.5 (29.3–33.9)	8.7 (7.4–10.2)
144	1043	29.2 (26.3–31.9)	7.5 (6.0–9.2)	1293	31.9 (29.4–34.6)	8.5 (7.0–10.2)	1484	32.1 (29.8–34.6)	8.6 (7.2–10.2)
192	917	32.1 (29.5–35.2)	8.5 (6.8–10.5)	1083	32.6 (29.8–35.5)	9.3 (7.7–11.2)	1240	32.9 (30.3–35.6)	9.2 (7.6–10.9)
240	690	34.2 (30.7–37.9)	9.6 (7.5–12.0)	751	36.4 (32.9–39.9)	10.7 (8.5–13.1)	901	35.7 (32.6–39.0)	10.4 (8.5–12.6)
288	506	37.0 (32.7–41.3)	11.5 (8.8–14.6)	568	40.7 (36.6–44.8)	13.7 (11.0–16.8)	678	38.2 (34.5–42.0)	13.0 (10.5–15.7)
336	315	36.8 (31.5–42.4)	12.1 (8.7–16.2)	357	39.5 (34.4–44.8)	13.2 (9.8–17.1)	434	39.4 (34.8–44.2)	13.6 (10.5–17.2)
384	294	40.5 (34.8–46.3)	13.3 (9.6–17.7)	337	43.6 (38.3–49.1)	13.9 (10.4–18.1)	394	42.6 (37.7–47.7)	13.2 (10.0–16.9)
432	138	37.0 (28.9–45.6)	10.9 (6.2–17.3)	173	39.9 (32.5–47.6)	12.1 (7.7–18.0)	202	41.1 (34.2–48.2)	12.4 (8.2–17.7)

VL, viral load.